Proteomic biomarkers predicting lymph node involvement in serum of cervical cancer patients. Limitations of SELDI-TOF MS

Proteome Science

Volumn 10, Issue 1, 2012, Pages

  Van Gorp, Toon ^a,b   Cadron, Isabelle ^a,c   Daemen, Anneleen ^a,d,e   De Moor, Bart ^d   Waelkens, Etienne ^a   Vergote, Ignace ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Department of Obstetrics and Gynaecology AZ Turnhout ^*  (Belgium)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ESAT SCD SISTA   (Belgium)

Author keywords

Biomarker; Cervical cancer; Lymph node; Recurrence; SELDI TOF MS

Indexed keywords

ALBUMIN; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; FIBRINOGEN; HAPTOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; OROSOMUCOID; PREALBUMIN; TRANSFERRIN; TRYPSIN INHIBITOR;

ADENOCARCINOMA; ADULT; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOLOGY; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; PROTEOMICS; RECURRENT DISEASE; SQUAMOUS CELL CARCINOMA; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; UTERINE CERVIX CANCER;

EID: 84862224828     PISSN: None     EISSN: 14775956     Source Type: Journal    
DOI: 10.1186/1477-5956-10-41     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet 2009, 105:107-108. 10.1016/j.ijgo.2009.02.009, 19342051.
3. Gien LT, Covens A. Lymph node assessment in cervical cancer: prognostic and therapeutic implications. J Surg Oncol 2009, 99:242-247. 10.1002/jso.21199, 19048600.
4. Tanaka Y, Sawada S, Murata T. Relationship between lymph node metastases and prognosis in patients irradiated postoperatively for carcinoma of the uterine cervix. Acta Radiol Oncol 1984, 23:455-459. 10.3109/02841868409136048, 6099039.
5. Sakuragi N, Satoh C, Takeda N, Hareyama H, Takeda M, Yamamoto R, Fujimoto T, Oikawa M, Fujino T, Fujimoto S. Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with stages IB, IIA, and IIB cervical carcinoma treated with radical hysterectomy. Cancer 1999, 85:1547-1554. 10.1002/(SICI)1097-0142(19990401)85:7<1547::AID-CNCR16>3.0.CO;2-2, 10193945.
6. Benedetti-Panici P, Maneschi F, D'Andrea G, Cutillo G, Rabitti C, Congiu M, Coronetta F, Capelli A. Early cervical carcinoma: the natural history of lymph node involvement redefined on the basis of thorough parametrectomy and giant section study. Cancer 2000, 88:2267-2274. 10.1002/(SICI)1097-0142(20000515)88:10<2267::AID-CNCR10>3.0.CO;2-9, 10820348.
7. Inoue T, Morita K. The prognostic significance of number of positive nodes in cervical carcinoma stages IB, IIA, and IIB. Cancer 1990, 65:1923-1927. 10.1002/1097-0142(19900501)65:9<1923::AID-CNCR2820650909>3.0.CO;2-M, 2372764.
8. Kamura T, Shigematsu T, Kaku T, Shimamoto T, Saito T, Sakai K, Mitsumoto M, Nakano H. Histopathological factors influencing pelvic lymph node metastases in two or more sites in patients with cervical carcinoma undergoing radical hysterectomy. Acta Obstet Gynecol Scand 1999, 78:452-457. 10.1080/j.1600-0412.1999.780520.x, 10326894.
9. Lai CH, Chang HC, Chang TC, Hsueh S, Tang SG. Prognostic factors and impacts of adjuvant therapy in early-stage cervical carcinoma with pelvic node metastases. Gynecol Oncol 1993, 51:390-396. 10.1006/gyno.1993.1309, 7509304.
10. Lee YN, Wang KL, Lin MH, Liu CH, Wang KG, Lan CC, Chuang JT, Chen AC, Wu CC. Radical hysterectomy with pelvic lymph node dissection for treatment of cervical cancer: a clinical review of 954 cases. Gynecol Oncol 1989, 32:135-142. 10.1016/S0090-8258(89)80024-1, 2910773.
11. Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, Favini G, Ferri L, Mangioni C. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997, 350:535-540. 10.1016/S0140-6736(97)02250-2, 9284774.
12. Green J, Kirwan J, Tierney J, Vale C, Symonds P, Fresco L, Williams C, Collingwood M. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev 2005, 20:CD002225.
13. Bipat S, Glas AS, Van der Velden J, Zwinderman AH, Bossuyt PM, Stoker J. Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: a systematic review. Gynecol Oncol 2003, 91:59-66. 10.1016/S0090-8258(03)00409-8, 14529663.
14. Selman TJ, Mann C, Zamora J, Appleyard TL, Khan K. Diagnostic accuracy of tests for lymph node status in primary cervical cancer: a systematic review and meta-analysis. Can Med Assoc J 2008, 178:855-862.
15. Van Gorp T, Cadron I, Vergote I. The utility of proteomics in gynecologic cancers. Curr Opin Obstet Gynecol 2011, 23:3-7. 10.1097/GCO.0b013e32834156e5, 21235022.
16. Anderson NL, Anderson NG. The human plasma proteome-history, character, and diagnostic prospects. Mol Cell Proteomics 2002, 1:845-867. 10.1074/mcp.R200007-MCP200, 12488461.
17. Roche S, Tiers L, Provansal M, Seveno M, Piva MT, Jouin P, Lehmann S. Depletion of one, six, twelve or twenty major blood proteins before proteomic analysis: the more the better?. J Proteomics 2009, 72:945-951. 10.1016/j.jprot.2009.03.008, 19341827.
18. Tu C, Rudnick PA, Martinez MY, Cheek KL, Stein SE, Slebos RJ, Liebler DC. Depletion of abundant plasma proteins and limitations of plasma proteomics. J Proteome Res 2010, 9:4982-4991. 10.1021/pr100646w, 2948641, 20677825.
19. Welberry Smith MP, Wood SL, Zougman A, Ho JT, Peng J, Jackson D, Cairns DA, Lewington AJ, Selby PJ, Banks RE. A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom-up proteomic analyses. Proteomics 2011, 11:2222-2235. 10.1002/pmic.201100005, 3262148, 21548096.
20. Yadav AK, Bhardwaj G, Basak T, Kumar D, Ahmad S, Priyadarshini R, Singh AK, Dash D, Sengupta S. A systematic analysis of eluted fraction of plasma post immunoaffinity depletion: implications in biomarker discovery. PLoS One 2011, 6:e24442. 10.1371/journal.pone.0024442, 3168506, 21931718.
21. Dijkstra M, Vonk RJ, Jansen RC. SELDI-TOF mass spectra: a view on sources of variation. J Chromatogr B Anal Technol Biomed Life Sci 2007, 847:12-23.
22. Wong YF, Cheung TH, Lo KWK, Wang VW, Chan CS, Ng TB, Chung TKH, Mok SC. Protein profiling of cervical cancer by protein-biochips: proteomic scoring to discriminate cervical cancer from normal cervix. Cancer Lett 2004, 211:227-234. 10.1016/j.canlet.2004.02.014, 15219946.
23. Lin YW, Lai HC, Lin CY, Chiou JY, Shui HA, Chang CC, Yu MH, Chu TY. Plasma proteomic profiling for detecting and differentiating in situ and invasive carcinomas of the uterine cervix. Int J Gynecol Cancer 2006, 16:1216-1224. 10.1111/j.1525-1438.2006.00583.x, 16803509.
24. Gemoll T, Roblick UJ, Auer G, Jornvall H, Habermann JK. SELDI-TOF serum proteomics and colorectal cancer: a current overview. Arch Physiol Biochem 2010, 116:188-196. 10.3109/13813455.2010.495130, 20615064.
25. Gast MC, Schellens JH, Beijnen JH. Clinical proteomics in breast cancer: a review. Breast Cancer Res Treat 2009, 116:17-29. 10.1007/s10549-008-0263-3, 19082706.
26. Westgard JO, Groth T, Aronsson T, de Verdier CH. Combined Shewhart-cusum control chart for improved quality control in clinical chemistry. Clin Chem 1977, 23:1881-1887.
27. Gullo F, Ponti G, Tagarelli A, Tradigo G, Veltri P. MaSDA: a system for analyzing mass spectrometry data. Comput methods programs biomed 2009, 95:S12-S21. 10.1016/j.cmpb.2009.02.011, 19344974.
28. Meuleman W, Engwegen JY, Gast MC, Beijnen JH, Reinders MJ, Wessels LF. Comparison of normalisation methods for surface-enhanced laser desorption and ionisation (SELDI) time-of-flight (TOF) mass spectrometry data. BMC Bioinforma 2008, 9:88.
29. Suykens JAK, Van Gestel T, De Brabanter J, De Moor B, Vandewalle J. Least Squares Support Vector Machines 2002, Singapore: World Scientific Pub. Co.
30. Daemen A, Gevaert O, Ojeda F, Debucquoy A, Suykens JA, Sempoux C, Machiels JP, Haustermans K, De MB. A kernel-based integration of genome-wide data for clinical decision support. Genome Med 2009, 1:39. 10.1186/gm39, 2684660, 19356222.